Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LTA4H | P09960 | 5/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MASP2 | O00187 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359968 | 0.86 | LTA4H (0.56) | RAB9ANPC1KMT2ALTA4HGRIN1 | |
| SCHEMBL29795482 | 0.86 | LTA4H (0.56) | RAB9ANPC1KMT2ALTA4HGRIN1 | |
| SCHEMBL14547183 | 0.83 | LTA4H (0.54) | RAB9ANPC1KMT2ALTA4HGRIN1 | |
| SCHEMBL7857823 | 0.82 | ALDH1A1 (0.58) | RAB9ANPC1KMT2ALTA4HALDH1A1 | |
| SCHEMBL2967288 | 0.81 | TP53 (0.53) | RAB9AGRIN1GRIN2BALDH1A1MAPT | |
| SCHEMBL2168662 | 0.80 | LTA4H (0.54) | RAB9ANPC1KMT2ALTA4HGRIN1 | |
| SCHEMBL2382054 | 0.80 | LTA4H (0.51) | RAB9ANPC1KMT2ALTA4HGRIN1 | |
| SCHEMBL5598128 | 0.80 | LTA4H (0.54) | RAB9ANPC1KMT2ALTA4HGRIN1 | |
| SCHEMBL17491662 | 0.78 | MAPK1 (0.49) | RAB9ANPC1KMT2ALTA4HALDH1A1 | |
| SCHEMBL570314 | 0.77 | AMY1A (0.44) | RAB9ANPC1KMT2ALTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601192-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-2687529-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-07-13 | — | — | EP | disclosed |
| EP-2982676-A1 | Benzimidazo[2,1-B]benzoxazoles for electronic applications | Idemitsu Kosan Co., Ltd. (JP) | 2016-02-10 | — | — | EP | disclosed |
| US-9029388-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| US-9029536-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| EP-2687529-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20130331409-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-12 | — | — | US | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| EP-2601192-A1 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012018909-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE10A, PDE3A, PDE2A | RAB9A 64/4885NPC1 3068/4885KMT2A 780/4885 |
| US-20130331409-A1 | CONDENSED HETEROCYCLIC COMPOUND | PDE10A, PDE5A, PDE3B | RAB9A 93/4885NPC1 4172/4885KMT2A 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.